BioInvent’s BI-1808 Plus Keytruda Shows Strong Ovarian Cancer Signal in Phase 2a

BioInvent International AB ( (SE:BINV) ) has shared an update.

BioInvent International AB reported encouraging interim Phase 2a data for its TNFR2‑targeting antibody BI‑1808 in combination with Merck’s PD‑1 inhibitor Keytruda in heavily pretreated advanced ovarian cancer. The regimen, given without chemotherapy, achieved a 24% confirmed objective response rate and 56% disease control rate in 25 patients, including a complete response and multiple durable responses beyond 10 months.

The combination showed substantially improved efficacy versus historical pembrolizumab monotherapy benchmarks in this setting, with preliminary median progression‑free survival of 10.3 months and activity across both high‑grade serous and clear cell subtypes. Safety was favorable with low treatment‑related discontinuations, and translational data demonstrated robust Treg depletion and CD8+ T‑cell activation, supporting the mechanism and potential to reposition PD‑1 inhibitors in difficult‑to‑treat cancers as cohort expansion progresses.

The most recent analyst rating on (SE:BINV) stock is a Buy with a SEK90.00 price target. To see the full list of analyst forecasts on BioInvent International AB stock, see the SE:BINV Stock Forecast page.

More about BioInvent International AB

BioInvent International AB, listed on Nasdaq Stockholm, is a Swedish biotech company specializing in the discovery and development of novel immune‑modulatory antibodies for cancer treatment. The company focuses on first‑in‑class mechanisms that enhance the effectiveness of existing immunotherapies in hard‑to‑treat solid tumors, aiming to address major unmet medical needs in oncology.

Average Trading Volume: 120,943

Technical Sentiment Signal: Sell

Current Market Cap: SEK1.7B

For a thorough assessment of BINV stock, go to TipRanks’ Stock Analysis page.